On November 18, 2026, the European Commission granted marketing authorization to Biocon Limited for Pebrilzo, a biosimilar version of pertuzumab. This approval allows Pebrilzo to be used in the European Union for treating HER2-positive breast cancer at multiple stages, including early, locally advanced, inflammatory, and metastatic forms of the disease.
Understanding Pebrilzo and Its Role in Breast Cancer Treatment
Pebrilzo is a 420 mg concentrate designed for infusion, intended to be administered alongside trastuzumab and chemotherapy. It targets HER2-positive breast cancer, a subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein, which promotes cancer cell growth. By blocking HER2, Pebrilzo helps to slow or stop the progression of the cancer.
This biosimilar is significant because it is the first to receive European Commission authorization following a tailored clinical approach by the European Medicines Agency (EMA). The EMA’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on the drug on September 17, 2026, paving the way for this approval.
Key Facts About Pebrilzo and Its Approval
- Mechanism of action: Pertuzumab, the active component in Pebrilzo, binds to the HER2 receptor at the HER3-binding domain, preventing the formation of HER2–HER3 dimers, which are crucial for signaling pathways that promote tumor growth.
- Complementary treatment: Trastuzumab, used alongside Pebrilzo, targets a different domain on the HER2 receptor. Together, these antibodies effectively block HER2 function.
- Manufacturing process: Pertuzumab is a monoclonal antibody produced recombinantly in Chinese hamster ovary (CHO) cells.
- Reference product: Pebrilzo is highly similar to Perjeta, the original pertuzumab product authorized in the EU since March 4, 2013.
- US approval: The US Food and Drug Administration approved Pebrilzo (pertuzumab-qcay) on November 16, 2026, for adults with HER2-positive metastatic and early breast cancer.
- Launch plans: Biocon aims to launch Pebrilzo in the EU and UK in the first quarter of 2027, with a licensed US launch expected in the third quarter of 2028, following a global patent settlement and licensing agreement with Genentech.
Why This Approval Matters for Cancer Treatment and Access
Biocon’s Pebrilzo approval marks a significant step in expanding access to affordable biologic therapies for breast cancer patients. Biosimilars like Pebrilzo provide more cost-effective alternatives to original biologic drugs without compromising efficacy or safety. This can reduce treatment costs and increase availability, especially in regions where high prices limit patient access.
Biocon’s chief executive and managing director, Shreehas Tambe, highlighted that this approval strengthens the company’s oncology portfolio and underscores its commitment to making cancer treatments more accessible globally. The introduction of Pebrilzo is expected to enhance treatment options for patients with HER2-positive breast cancer in Europe and beyond.
Frequently Asked Questions
Q: What is a biosimilar?
A biosimilar is a biologic medical product highly similar to an already approved original biologic drug, with no meaningful differences in safety or effectiveness.
Q: How does Pebrilzo work against HER2-positive breast cancer?
Pebrilzo blocks the HER2 receptor’s ability to form dimers with HER3, which are essential for cancer cell growth signals, thereby inhibiting tumor progression.
Q: When will Pebrilzo be available in the US and Europe?
Biocon plans to launch Pebrilzo in the European Union and United Kingdom in early 2027, with a US launch expected in late 2028 after licensing agreements are finalized.
